Navigating Changes in Dermatology and Clinical Research Efforts

Image Credit: © Wasaphol - stock.adobe.com

Every summer, Dermatology Times highlights the season’s busiest clinical meetings and the studies, innovations, and stories shaping dermatologic care. As summer peaks, our July issue spotlights changes that may shape the direction of dermatologic research and clinical priorities in the coming months.

This month’s cover feature by Nicole A. Negbenebor, MD, spotlights surgical interventions in hidradenitis suppurativa (HS). Patients with HS often benefit from a combination of systemic therapies and procedural interventions tailored to their disease severity, lesion location, and personal preferences. While intralesional corticosteroids, deroofing, and excision offer effective relief and lower recurrence rates, maintaining long-term management remains essential for optimal outcomes.

The issue also features a review of practical guidance on photoprotection during pregnancy, focusing on UV and visible light exposure and the unique dermatologic needs of expectant patients. Zoe Diana Draelos, MD, explores whether artificial intelligence is beginning to reshape the formulation and performance of skin care products. Matthew Zirwas, MD, shares insights on data evaluating the safety-efficacy balance in nonsteroidal psoriasis therapies. Jennifer Fisher, MMSc, PA-C, details a rare case of abrocitinib-induced psoriasis-like eruption.

In acne and rosacea, Naiem Issa, MD, PhD, discusses recent research observing distinct skin microbiome signatures that may soon inform more targeted treatment strategies. In skin cancer, Renata Block, DMSc, MMS, PA-C, shares the stories of 3 melanoma survivors—patients who speak candidly about diagnosis, treatment, and the importance of early detection and advocacy.

The issue also features a recap of this year’s Revolutionizing Atopic Dermatitis Conference, where breakthrough discussions on JAK inhibitors, real-world outcomes, and access equity took center stage.

As always, Dermatology Times delivers the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert perspectives. Stay informed with the latest data—subscribe to Dermatology Times’ e-newsletters; follow us on Facebook, LinkedIn, and X.

Mike Hennessy Jr

Mike Hennessy Jr

Chairman and CEO
MJH Life Sciences